EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of empagliflozin and its combination with docetaxel on LNCaP and DU- 145 prostate cancer cell lines: cytotoxicity and molecular pathway analysis

Ahmet Cumaoğlu, Selda Nur Akdeniz, Ahmad Karzoon, Mohamed Alaama, Mükerrem Betül Yerer

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-025-04132-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Ahmet Cumaoğlu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Türkiye. ahmetcumaoglu@erciyes.edu.tr. Hauptthemen laut MEDLINE: Docetaxel, Benzhydryl Compounds, Prostatic Neoplasms, Glucosides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Erciyes University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have gained attention for their potential therapeutic applications in cancer treatment. Recent Mendelian randomization and observational analyses support the protective role of SGLT2 inhibition in reducing prostate cancer risk. Additionally, SGLT2 expression in prostate cancer patient samples has been confirmed through immunohistochemistry. The therapeutic potential of empagliflozin, a selective SGLT2 inhibitor, in treating prostate cancer, either alone or with chemotherapeutic agents like docetaxel, remains largely unexplored. This study investigated the cytotoxic and synergistic effects of empagliflozin in combination with docetaxel in LNCaP and DU- 145 prostate cancer cells. Cell viability was assessed using the MTT assay, and synergy was evaluated using the Chou-Talalay method. Western blot analysis was conducted to examine the effects of empagliflozin, alone and in combination with docetaxel, on key molecular targets, including p-AMPKα, p-p70S6 K1, p-PRAS40, and p-Akt. Empagliflozin exhibited concentration-dependent cytotoxic effects in both LNCaP and DU- 145 cells, with a higher potency observed in DU- 145 cells. When combined with docetaxel, empagliflozin demonstrated synergistic activity, as indicated by combination index values < 1. Empagliflozin upregulated p-AMPKα and downregulated p-p70S6 K1 and p-PRAS40. The combination with docetaxel further enhanced these effects. Notably, empagliflozin alone downregulated p-Akt in LNCaP cells but not in DU- 145 cells, highlighting cell-line-specific differences. Empagliflozin reduces prostate cancer cell viability and enhances the cytotoxic effects of docetaxel, suggesting a promising combination strategy for prostate cancer therapy. Additional in vivo studies and clinical trials are needed to assess the translational relevance of these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelBenzhydryl CompoundsProstatic NeoplasmsGlucosidesSodium-Glucose Transporter 2 InhibitorsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsHumansMaleCell Line, TumorCell SurvivalDrug SynergismSignal TransductionDose-Response Relationship, Drug

Stichwörter der Autor:innen

AMPKαEmpagliflozinP70S6 K1PGC- 1αPRAS40Prostate cancer

Substanzen

empagliflozinDocetaxelBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biochemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Türkiye. ahmetcumaoglu@erciyes.edu.tr.
  • Department of Biochemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Türkiye.
  • Department of Pharmacology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye.
  • Drug Application and Research Center (ERFARMA), Biopep Medikal İlaç Sanayi Ve Ticaret, Erciyes University, Kayseri, Türkiye.
  • Department of Pharmacology, Faculty of Pharmacy, Erciyes University, Kayseri, Türkiye.

Förderung

  • Erciyes University

Zitieren

APA

Cumaoğlu, A., Akdeniz, S. N., Karzoon, A., Alaama, M., & Yerer, M. B. (2025). Effects of empagliflozin and its combination with docetaxel on LNCaP and DU- 145 prostate cancer cell lines: cytotoxicity and molecular pathway analysis. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04132-9

Vancouver

Cumaoğlu A, Akdeniz SN, Karzoon A, Alaama M, Yerer MB. Effects of empagliflozin and its combination with docetaxel on LNCaP and DU- 145 prostate cancer cell lines: cytotoxicity and molecular pathway analysis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04132-9

BibTeX
@article{Cumaolu2025,
  author = {Cumaoğlu, Ahmet and Akdeniz, Selda Nur and Karzoon, Ahmad and Alaama, Mohamed and Yerer, Mükerrem Betül},
  title = {Effects of empagliflozin and its combination with docetaxel on LNCaP and DU- 145 prostate cancer cell lines: cytotoxicity and molecular pathway analysis},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-025-04132-9}
}
Kostenlos starten →